01—Abstract
Summary
Summary of the 10-K filed March 7, 1994. Cited figures are marked; the original filing is the authoritative source.
3M's 1993 Form 10-K shows a company that grew modestly in a difficult year.
Worldwide net sales rose 1.0% to $14.02 billiona, with U.S. sales up about 3% and international sales down about 1% (the stronger dollar and currency translation cut international results by roughly 6 points). Net income rose 2.5% to $1.263 billion, or $5.82 per share, and operating income fell 1.9% to $1.956 billion as negative currency effects and pricing pressure offset volume gains. Management cited a challenging environment: recessions in Europe and Japan, a soft U.S. health care market, and intense price competition, particularly in memory technologies.
Return on average stockholders' equity was 19.1%, and more than 25% of sales came from products introduced in the prior four years. Capital discipline and shareholder returns were central to the year. Capital expenditures fell 9.3% to $1.112 billionb, while operating cash flow was $2.091 billion.
Dividends rose 3.8% to $3.32c per share, and share repurchases reached $706 million. In February 1994 the board raised the quarterly dividend 6% to 88 cents, declared a two-for-one stock split (distribution around April 8, 1994), and authorized repurchase of up to 12 million pre-split shares. The company's AAA long-term ratings and 78 consecutive years of dividend payments underscore its balance sheet strength.
The principal risk flagged for investors is litigation. 3M was named in 3,054 silicone gel mammary implant claims covering 8,842 individual claimants. The company was excluded from the February 1994 global settlement among other defendants and is negotiating separately.
Management's general counsel opined that insurance coverage appears sufficient and no insurers had denied coverage, so management believes these matters will not be material to financial position or results. Environmental liabilities are also described as uncertain, with accruals reviewed quarterly.
02—Key points
Key Highlights
- Net sales rose 1.0% to $14.02 billion; U.S. sales up about 3% to $7.13 billion while international sales fell about 1% to $6.89 billion due to currency translation (about -6 points).
- Net income increased 2.5% to $1.263 billion ($5.82 per share), while operating income declined 1.9% to $1.956 billion.
- Return on average stockholders' equity was 19.1% (up from 18.8%), and return on capital employed was 19.1% (down from 19.7%).
- Currency changes reduced 1993 net income by about $62 million, or 29 cents per share; pricing pressure, especially in memory technologies, weighed on margins.
- Capital expenditures fell 9.3% to $1.112 billion; operating cash flow was $2.091 billion; stock repurchases totaled $706 million.
- Board raised the quarterly dividend 6% to 88 cents and declared a two-for-one stock split (record date March 15, 1994), plus authorized repurchase of up to 12 million pre-split shares.
- Silicone gel mammary implant litigation involves 3,054 claims covering 8,842 claimants; 3M was excluded from the February 1994 global settlement, and management believes insurance coverage is sufficient.
03—Questions
Frequently Asked Questions
How did 3M perform financially in 1993?
3M grew sales modestly, with worldwide net sales up 1.0% to $14.02 billion. Net income rose 2.5% to $1.263 billion, or $5.82 per share, helped by lower interest expense and higher investment income, even though operating income fell 1.9%. Currency headwinds and pricing pressure were the main drags.
What is the impact of the mammary implant lawsuits on 3M?
3M faces 3,054 claims and lawsuits covering 8,842 individual claimants, though it is unclear how many involve 3M-manufactured products versus other manufacturers. 3M sold its implant business in 1984, which it estimates represented about 7% of cumulative mammary implant sales. The company was not part of the February 1994 global settlement and is negotiating separately. Management believes insurance coverage is sufficient and that the matters will not be material, but the outcome remains uncertain.
Is 3M's dividend growing and how secure is it?
Yes. Dividends paid rose 3.8% to $3.32 per share in 1993, and in February 1994 the board raised the quarterly dividend 6% to 88 cents. 3M has paid dividends for 78 consecutive years, and its AAA long-term credit ratings and $2.09 billion in operating cash flow, which more than covered capital spending and dividends, support its continuity.
What are the main challenges to 3M's growth outlook for 1994?
Management expects slightly better global growth, with improvement in the second half, but warns that pricing will remain highly competitive and that currency fluctuations could again significantly hurt results. The Information, Imaging and Electronic sector faces continued price pressure, and the Life Sciences sector remains exposed to uncertainty over U.S. health care reform. R&D and capital spending are expected to stay near 1993 levels.
What is the significance of the two-for-one stock split?
The board declared a two-for-one stock split, with shares distributed around April 8, 1994, to holders of record on March 15, 1994. The split doubles the number of shares outstanding (about 214 million at January 31, 1994) and halves the per-share price, which can improve trading liquidity and broaden retail ownership. It does not change the company's aggregate value.
04—Continue